5:02 PM
 | 
Aug 13, 2009
 |  BC Extra  |  Company News

FDA approves King's Embeda

King Pharmaceuticals Inc. (NYSE:KG) said FDA approved Embeda to manage moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda is an extended-release formulation of morphine, which includes a sequestered pellet core of naltrexone. The label includes...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >